Hengrui Medicine (600276): Novo licensing deal reinforces the strategic value of Hengrui's next-generation obesity pipeline

Overview

This event commentary assesses Hengrui Medicine's licensing agreement with Novo for HRS-1596. Goldman Sachs sees the transaction as external validation of Hengrui's early-stage obesity pipeline, broader cardiometabolic strategy and increasingly diversified overseas licensing story, while maintaining its Buy rating.

Core views

Hengrui has granted Novo exclusive ex-China rights to HRS-1596, a Phase I-ready oral GLP-1/GIP peptide designed for once-weekly administration. The deal provides US$300mn upfront, potential development, regulatory and commercial milestones of up to US$2.3bn, and royalties on future sales. HRS-1596 has received Chinese IND approval for obesity and type 2 diabetes studies; Hengrui plans to begin Phase I trials in China in 2026 and Goldman Sachs expects preliminary data in 2027. Although the asset remains very early stage, the report views Novo's upfront payment as evidence of strategic interest in differentiated oral incretin therapies and as additional validation of Hengrui's global metabolic franchise. The report argues that the agreement supports a broader obesity and metabolic-disease strategy rather than being solely an endorsement of HRS-1596. Hengrui entered GLP-1 later than global peers but has assembled a pipeline aimed at differentiation across efficacy, convenience and mechanism. HRS-9531, an oral GLP-1/GIP agonist identified by management as a strategic asset, generated Phase II weight loss of 12.1% at week 26, or 9.8% placebo-adjusted, with an 11.4% vomiting rate. Beyond multi-target agonists intended to improve efficacy, Hengrui is pursuing oral and long-acting formulations for convenience, as well as INHBE and amylin-based approaches intended to preserve muscle mass and broaden metabolic benefits. Goldman Sachs places the Novo transaction within Hengrui's expanding overseas business-development record beyond oncology. It believes this diversification should reinforce investor confidence in the cardiometabolic pipeline. More broadly, the institution expects future growth to be driven by innovative drugs—including HER2 ADC, CDK4/6, AR antagonist, PI3Ki, obesity and autoimmune assets—after the major impact of volume-based procurement price cuts was largely reflected and reset to a lower base in 2022. It notes that Hengrui has launched nine drugs with sales above Rmb1bn in recent years, including four innovative drugs, supported by its sales force. Goldman Sachs maintains Buy and a 12-month target price of Rmb73.86, versus a Rmb45.62 closing price on 29 September 2026, implying 61.9% upside. Its valuation combines Rmb39.3bn for the generics business, using a five-year exit P/E of 10x, with Rmb390.7bn for innovative drugs using a risk-adjusted DCF based on a 9.0% WACC and 3% terminal growth. The report's central valuation view is that the current valuation largely reflects Hengrui's China prospects, while overseas progress could provide further upside.

Analysis framework

Goldman Sachs first evaluates the commercial terms, development stage and strategic implications of the Novo licensing agreement. It then compares Hengrui's obesity pipeline across efficacy, tolerability, formulation and novel mechanisms, and connects the deal to Hengrui's broader overseas business-development strategy. The target price combines an exit P/E valuation for generics with a risk-adjusted discounted-cash-flow valuation for innovative drugs.

Methodology notes

• Valuation methodsP/E and PEG Valuation

  Five-year exit P/E valuation for the generics business

  The report applies a 10x five-year exit P/E multiple to value Hengrui's generics business at Rmb39.3bn.

• Valuation methodsDCF (Discounted Cash Flow)

  Risk-adjusted DCF for innovative drugs

  The report discounts risk-adjusted innovative-drug cash flows using a 9.0% WACC and 3% terminal growth rate, deriving Rmb390.7bn of value.

• Industry AnalysisUpstream-Midstream-Downstream Transmission

  Overseas licensing and global business-development strategy

  The report uses the Novo agreement and prior licensing activity to assess how external partners may validate and monetize Hengrui's innovation pipeline outside China.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Hengrui Medicine (600276.SS)

  Primary covered company; Novo licensing of HRS-1596 supports the value of its obesity and cardiometabolic pipeline.

  Strengths

  Diversified next-generation obesity pipeline, competitive Phase II HRS-9531 data, established sales team and expanding overseas business development.

  Weaknesses

  Entered the GLP-1 field later than global peers; HRS-1596 remains early stage.

  Comparison

  Novo's commitment is presented as validation by a global obesity leader; Hengrui seeks differentiation beyond weight-loss efficacy alone.

  Risks

  Slower innovative-drug ramp after NRDL listing, late-stage R&D failures, higher global-expansion costs, drug price cuts and weaker license-out progress.

• Novo

  Ex-China licensee for HRS-1596 and strategic counterparty validating Hengrui's oral incretin asset.

  Strengths

  Described as a global leader in obesity.

  Comparison

  Its US$300mn upfront commitment is presented as evidence of interest in differentiated oral incretin therapies.

Key data

• HRS-1596 upfront paymentUS$300mnNovo payment for exclusive ex-China rights.
• HRS-1596 potential milestonesUp to US$2.3bnDevelopment, regulatory and commercial milestones, plus future-sales royalties.
• HRS-1596 development timingPhase I China trials in 2026; preliminary data expected in 2027The asset has Chinese IND approval for obesity and type 2 diabetes studies.
• HRS-9531 Phase II weight loss12.1% at week 269.8% placebo-adjusted.
• HRS-9531 vomiting rate11.4%Reported as favorable tolerability.
• 12-month target priceRmb73.86Versus Rmb45.62 closing price on 29 September 2026; 61.9% implied upside.
• Innovative-drug valuationRmb390.7bnRisk-adjusted DCF using 9.0% WACC and 3% terminal growth.
• Generics valuationRmb39.3bnBased on a five-year exit P/E of 10x.

Impact & implications

The report sees Novo's commitment as a strategic validation of Hengrui's differentiated oral incretin approach and an indication that overseas licensing can become an additional value driver beyond China and oncology. It argues that progress in innovative drugs and global business development could support value not fully reflected in the current valuation.

Risks

• Innovative drugs may ramp up more slowly after NRDL listing.
• Key late-stage R&D programs may fail.
• R&D and administrative expenses for global expansion may exceed expectations.
• Price cuts for generics and innovative drugs may be greater than expected.
• License-out and broader go-global progress may fall below expectations.

What to watch

• Initiation of HRS-1596 Phase I trials in China in 2026 and preliminary data expected in 2027.
• Development of Hengrui's differentiated obesity pipeline, including HRS-9531 and other multi-target, oral and long-acting programs.
• Progress in overseas licensing and global business-development transactions.
• Commercial ramp-up of innovative drugs and the extent of further pricing pressure.